CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-13 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −129,172 | 0 | ||
| 2025-08-12 | Taub Rebecca Director | Option exercise 10b5-1 | +43,263 | $9.45 | $409K | 504,307 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −3,580 | $350.87 | $1.3M | 500,727 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −2,870 | $351.60 | $1.0M | 497,857 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −1,175 | $352.45 | $414K | 496,682 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −4,587 | $354.04 | $1.6M | 492,095 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −6,479 | $354.97 | $2.3M | 485,616 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −5,752 | $355.95 | $2.0M | 479,864 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −4,864 | $356.88 | $1.7M | 475,000 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −6,715 | $357.85 | $2.4M | 468,285 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −6,541 | $358.81 | $2.3M | 461,744 |
| 2025-08-12 | Taub Rebecca Director | Sale 10b5-1 | −700 | $359.71 | $252K | 461,044 |
| 2025-08-12 | Taub Rebecca Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −43,263 | 0 | ||
| 2025-08-12 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +43,605 | $9.45 | $412K | 230,769 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −3,303 | $350.93 | $1.2M | 227,466 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −3,202 | $351.59 | $1.1M | 224,264 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,382 | $352.61 | $487K | 222,882 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −4,768 | $354.06 | $1.7M | 218,114 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −6,546 | $355.00 | $2.3M | 211,568 |
| 2025-08-12 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −5,244 | $355.97 | $1.9M | 206,324 |
Page 19 of 82 · 1,629 trades